There are many ways our bodies jump into action to defend us from harmful viruses, such as SARS-CoV-2, which causes COVID-19. In order to get a sense of the goals of research on COVID-19 vaccines ...

Recombinant vector vaccines use a benign virus, into which pieces of the pathogen’s genome have been inserted. The choice of the benign vector depends on many factors, including its own transmission ...

Dublin, June 30, 2021 (GLOBE NEWSWIRE) -- The "Cancer Vaccines Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering. The global ...

Covina, April 10, 2023 (GLOBE NEWSWIRE) -- The Preventive Vaccine market accounted for US$ 39.45 Billion in 2020 and is estimated to be US$ 69.0 billion by 2030 and is anticipated to register a ...

The first recombinant virus-based vaccine for pigs employs a reverse genetic platform that was developed and refined at IIT Guwahati. Researchers at the Indian Institute of Technology (IIT ...

Recombinant quadrivalent influenza vaccine (RIV4) and standard egg-based quadrivalent inactivated IV (IIV4) show comparable effectiveness in reducing influenza-related hospitalization among older ...